Edgewise Therapeutics, Inc. EWTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.01M+2.4% | -$50.22M-23.5% | -$40.67M-12.6% | -$36.12M+11.5% | -$40.8M-2.9% | ||
| $537K+2.3% | $525K+5.0% | $500K0.0% | $500K-2.5% | $513K-11.1% | ||
| $8.72M-11.7% | $9.88M+22.1% | $8.09M+4.6% | $7.73M-14.6% | $9.06M+17.1% | ||
| $1.45M— | —— | —— | —— | $2.86M+3,007% | ||
| -$6.75M-252% | $4.43M— | —— | —— | -$6.08M-257% | ||
| -$3.05M-212% | $2.72M+109% | $1.3M-47.5% | $2.47M+67.3% | $1.48M+193% | ||
| -$196K-1.6% | -$193K-2.1% | -$189K-1.1% | -$187K-4.5% | -$179K— | ||
| -$42.54M-10.2% | -$38.59M-11.0% | -$34.78M-6.7% | -$32.58M+14.0% | -$37.87M-40.5% | ||
| $260K+256% | $73K-30.5% | $105K+209% | $34K-22.7% | $44K-83.9% | ||
| $108.88M+0.6% | $108.19M— | —— | —— | $151.12M+85.9% | ||
| $2.43M— | —— | —— | -$162.17M-469% | $43.9M— | ||
| $12.17M— | —— | —— | $187.1M+8,175% | $2.26M— | ||
| —— | —— | —— | —— | $38K— | ||
| $12.17M+206% | $3.98M+140% | $1.66M-99.1% | $188.23M+8,367% | $2.22M-23.2% | ||
| -$27.94M-284% | $15.15M+483% | $2.6M— | —— | $8.26M+363% | ||
| $1.01M-31.7% | $1.48M-27.9% | $2.06M-6.7% | $2.2M+14.6% | $1.92M-26.1% | ||
| $537K+2.3% | $525K+5.0% | $500K0.0% | $500K-2.5% | $513K-11.1% | ||
| -$6.75M-252% | $4.43M— | —— | —— | -$6.08M-257% | ||
| -$196K-1.6% | -$193K-2.1% | -$189K-1.1% | -$187K-4.5% | -$179K— | ||
| $635K-55.8% | $1.44M+162% | $548K+139% | -$1.42M-1,260% | $122K-88.9% | ||
| -$3.05M-212% | $2.72M+109% | $1.3M-47.5% | $2.47M+67.3% | $1.48M+193% | ||
| $3.97M-75.1% | $15.93M— | —— | —— | $15M+388% | ||
| —— | —— | —— | —— | $38K— | ||
| $41K-73.0% | $152K— | —— | —— | —— | ||
| $53K+6.0% | $50K+6.4% | $47K+6.8% | $44K+7.3% | $41K-21.2% | ||
| -$196K-1.6% | -$193K-2.1% | -$189K-1.1% | -$187K-4.5% | -$179K— | ||
| —— | —— | —— | —— | $395K— | ||
| -$42.8M-10.7% | -$38.67M-10.8% | -$34.88M-6.9% | -$32.62M+14.0% | -$37.91M-39.2% | ||
| -$42.8M-10.7% | -$38.67M-10.8% | -$34.88M-6.9% | -$32.62M+14.0% | -$37.91M-39.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Edgewise Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.